Successful treatment of diffuse large B-cell non-hodgkin lymphoma with modified CHOP (cyclophosphamide/doxorubicin/vincristine/ prednisone) chemotherapy and rituximab in a patient with Nijmegen syndrome

Clinical Lymphoma and Myeloma

Volumn 7, Issue 9, 2007, Pages 590-593

  Dumic, Miroslav ^a   Radman, Ivo ^a   Krnic, Nevena ^a   Nola, Marin ^a   Kusec, Rajko ^b   Begovic, Davor ^a   Labar, Boris ^a   Rados, Marko ^a  

^a KBC Zagreb   (Croatia)

^b University Hospital Dubrava ^*  (Croatia)

Author keywords

Chromosomal breakage syndrome; DNA repair; Monoclonal antibody; NBS1 gene; Nibrin

Indexed keywords

ANTIBIOTIC AGENT; CD20 ANTIBODY; CEFTRIAXONE; CYCLOPHOSPHAMIDE; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; METHYLPREDNISOLONE; MITOXANTRONE; MONOCLONAL ANTIBODY; NIBRIN; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADOLESCENT; ARTICLE; AUTOSOMAL RECESSIVE DISORDER; B CELL LYMPHOMA; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER SUSCEPTIBILITY; CASE REPORT; CHROMOSOME REARRANGEMENT; COMBINATION CHEMOTHERAPY; CROATIA; DNA REPAIR; FACIES; FEBRILE NEUTROPENIA; GENE MUTATION; GENETIC PREDISPOSITION; GROWTH RETARDATION; HUMAN; IMMUNE DEFICIENCY; LABORATORY TEST; LARGE CELL LYMPHOMA; LYMPHOMA; MALE; MEDICAL LITERATURE; MICROCEPHALY; MULTIPLE CYCLE TREATMENT; NIJMEGEN BREAKAGE SYNDROME; NONHODGKIN LYMPHOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSICAL EXAMINATION; PSYCHOLOGIC TEST; RADIOSENSITIVITY; TREATMENT OUTCOME;

EID: 37849050496     PISSN: 15579190     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2007.n.046     Document Type: Article

References (25)

1. Seemanová E, Passarge E, Beneskova D, et al. Familial microcephaly with notmal intelligence, immunodeficiency, and risk for lymphoreticulat malignancies: a new autosomal recessive disorder. Am J Med Genet 1985; 20:639-48.
2. Chrzanowska KH, Kleijer WJ, Krajewska-Walasek M, et al. Eleven Polish patients with microcephaly, immunodeficiency, and chromosomal instability: the Nijmegen bteakage syndrome. Am J Med Genet 1995; 57:462-71.
3. van der Burgt I, Chrzanowska KH, Smeets D, et al. Nijmegen breakage syndrome. J Med Genet 1996; 33:153-6.
4. Nijmegen breakage syndrome. The International Nijmegen Breakage Syndrome Study Group. Arch Dis Child 2000; 82:400-6.
5. Varon R, Seemanova E, Chrzanowska K, et al. Clinical ascertainment of Nijmegen breakage syndrome (NBS) and prevalence of the major mutation, 657del5, in three Slav populations. Eur J Hum Genet 2000; 8:900-2.
6. Varon R, Vissinga C, Platzer M, et al. Nibrin, a novel DNA double-strand break repair protein, is mutated in Nijmegen breakage syndrome. Cell 1998; 93:467-76.
7. Carney JP, Maser RS, Olivares H, et al. The hMre11/hRad50 protein complex and Nijmegen breakage syndrome: linkage of double-strand break repair to the cellular DNA damage response. Cell 1998; 93:477-86.
8. Matsuura S, Tauchi H, Nakamura A, et al. Positional cloning of the gene for Nijmegen breakage syndrome. Nat Genet 1998; 19:179-81.
9. Digweed M, Sperling K. Nijmegen breakage syndrome: clinical manifestation of defective response to DNA double-strand breaks. DNA Repair (Amst) 2004; 3:1207-17.
10. Weemaes CM, Smeets DF, van der Burgt CJ. Nijmegen breakage syndrome: a progress report. Int J Radiat Biol 1994; 66(suppl 6):S185-8.
11. Seidemann K, Tiemann M, Henze G, et al. Therapy for non-Hodgkin lymphoma in children with primary immunodeficiency: analysis of 19 patients from the BFM trials. Med Pediatr Oncol 1999; 33:536-44.
12. Seidemann K, Henze G, Beck JD, et al. Non-Hodgkin's lymphoma in pediattic patients with chromosomal breakage syndromes (AT and NBS): experience from the BFM trials. Ann Oncol 2000; 11 (suppl 1):141-5.
13. Paulli M, Viglio A, Boveri E, et al. Nijmegen breakage syndrome-associated T-cell-rich B-cell lymphoma: case report. Pediatr Dev Pathol 2000; 3:264-70.
14. Bakhshi S, Cerosaletti KM, Concannon P, et al. Medulloblastoma with adverse reaction to radiation therapy in nijmegen breakage syndrome. J Pediatr Hematol Oncol 2003; 25:248-51.
15. Distel L, Neubauer S, Varon R, et al. Fatal toxicity following radio-and chemotherapy of medulloblastoma in a child with unrecognized Nijmegen breakage syndrome. Med Pediatr Oncol 2005; 41:44-8.
16. Niehues T, Schellong G, Dörffel W, et al. Immunodeficiency and Hodgkin's disease: tteatment and outcome in the DAL HD78-90 and GPOH HD95 studies. Klin Padiatr 2003; 215:315-20.
17. Held G, Pöschel V, Pfreundschuh M. Rituximab for the treatment of diffuse large B-cell lymphomas. Expert Rev Anticancer Ther 2006; 6:1175-86.
18. Kropshofer G, Wehl G, Klein-Franke A, et al. B-cell lymphoma in a girl with ataxia teleangiectasia (A-T) treated with rituximab monotherapy. Pediatr Blood Cancer 2006; 46:528-9.
19. Rossi G, Zecca M, Marchi A, et al. Modified chop-chemotherapy plus rituximab fot diffuse large B-cell lymphoma complicating ataxia-telangiectasia. Br J Haematol 2003; 120:369-71.
20. Gregorek H, Chrzanowska KH, Michalkiewicz J, et al. Heterogeneity of humoral immune abnormalities in children with Nijmegen breakage syndrome: an 8-year follow-up study in a single centre. Clin Exp Immunol 2002; 130:319-24.
21. Vento S, Cainelli F. Infections in patients with cancer undergoing chemotherapy: aetiology, prevention, and treatment. Lancet Oncol 2003; 4:595-604.
22. Chrzanowska KH, Krajewska-Walasek M, Bialecka M, et al. Ovarian failure in female patients with Nijmegen breakage syndrome. Eur J Hum Genet 1996; 4(suppl 1):122.
23. Conley E, Spinner NB, Emanuel BS, et al. Chromosomal breakage syndrome with profound immunodeficiency. Blood 1986; 67:1251-1256.
24. Difilippantonio S, Celeste A, Fernandez-Capetillo O, et al. Role of Nbs1 in the activation of the Atm kinase revealed in humanized mouse models. Nat Cell Biol 2005; 7:675-85.
25. Kang J, Bronson RT, Xu Y. Targeted disruption of NBS1 reveals its roles in mouse development and DNA repair. Embo J 2002; 21:1447-55.